Background: Although statins vary in their effectiveness in lowering low-density lipoprotein cholesterol (LDL-C) and increasing high-density lipoprotein cholesterol (HDL-C) levels, there is little evidence that the degree of these changes can explain cardiac risk reduction in Japan. Our objective was to compare the efficacy of statins on serum lipid levels and to explore the association between those changes and cardiac events in patients after percutaneous coronary intervention (PCI).
he use of statins has revolutionized the management of people at risk for cardiovascular disease. Many previous studies have demonstrated that statin-induced decreases in low-density lipoprotein cholesterol (LDL-C) levels are related to risk reduction. 1,2 Hypercholesterolemia is a strong and independent risk factor of cardiac events, and several Western large trials have identified that intensive lipid-lowering treatment with atorvastatin resulted in a greater reduction in the progression of coronary atherosclerosis and prevention of cardiovascular events than moderate treatment with pravastatin. 3, 4 On the other hand, there is mounting circumstantial evidence that the ability of statins to increase high-density lipoprotein cholesterol (HDL-C) may also contribute to the benefit. 5- 7 The increase in HDL-C achieved by statins is independent of the decrease in LDL-C, and the HDL-C raising ability differs among statins. 8, 9 However, there are few reports evaluating whether differences in the lipid management powers of statins lead to a different prognosis in Japanese. 10, 11 Therefore we conducted a retrospective study to show the efficacy of statins on major adverse cardiac events (MACE) in patients after percutaneous coronary intervention (PCI) and to compare those effects among statins in Japanese patients.
Methods

Study Design
The present study was a retrospective, single-center observational study. The data of consecutive patients who underwent PCI in our hospital from 2001 to 2008 were examined. This study was conducted according to the guidelines for epidemiological studies issued by the Ministry of Health, Labor
Data Collection and Definitions
The data of baseline characteristics, laboratory data at baseline and at final observation, incidence of cardiac events, dates of initial PCI and final observation were collected. The study population was classified into 4 groups according to statin administration (pravastatin, atorvastatin, pitavastatin and no statin). Baseline characteristics consisted of age, gender, baseline body mass index (BMI), complicating disease such as diabetes mellitus and hypertension, smoking habit, type of coronary artery disease (CAD), type of device and concomitant medications. Values of LDL-C, HDL-C, non-HDL-C (defined as total cholesterol minus HDL-C), triglycerides and HbA1c at baseline and at final observation were obtained as laboratory data. Levels of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were also evaluated. The endpoint was a composite of cardiac sudden death, fatal or nonfatal myocardial infarction (MI), death from worsening of ; concomitant medications such as thienopyridine derivative, calcium-channel blocker, angiotensin-converting enzyme inhibitor (ACEI), angiotensin-receptor blocker (ARB), β-blocker, thiazide, loop diuretic, spironolactone, each statin, eicosapentaenoic acid (EPA), other lipid-lowering medications including fibrate, insulin, sulfonyl urea, biguanide, α-glucosidase inhibitor, thiazolidine; baseline levels, follow-up levels and percent changes in laboratory values including LDL-C, HDL-C, non-HDL-C, LDL-C/HDL-C ratio, triglycerides, HbA1c, fasting plasma glucose, creatinine, uric acid; baseline and follow-up levels of SBP, DBP and heart rate. Variables of P<0.05 in the univariate analysis were assessed in the multivariate analyses using a Cox proportional hazard model. We finally developed a multivariate Cox proportional hazard model with variables of P<0.05 in prior multivariate analysis to assess the preventive effect on cardiac events in each statin group compared with no statin group. The significance level was 5% 2-sided (2.5% 1-sided), and all statistical analyses were performed using JMP version 5.1 (SAS Institute, Cary, NC, USA).
Results
Baseline Characteristics
A total of 743 patients were examined in this study. The patients had received pravastatin (average dose: 10.3 mg, n=151), atorvastatin (11.3 mg, n=161), pitavastatin (2.3 mg, n=180), or no statin (n=251). Table 1 summarizes the baseline characteristics of the patients in the 4 groups. Because of the observational study design, significant differences in some variables were observed, such as age, BMI, diabetes mellitus and type of device, at baseline among the 4 groups. The no statin group included the highest age population; the pitavastatin group included the largest BMI population, and contained diabetic patients (55.6%) and DES-implanted patients (54.4%) with the most frequency. There were also significant differences in concomitant medications such as thienopyridine derivative, ACEI, ARB, β-blocker, loop diuretic, other lipidlowering medications (including mainly fibrates [79%, 27/ 34], resin, niacin and probucol), sulfonyl urea, biguanide and thiazolidine. All patients were treated with aspirin. There were significant differences in most laboratory variables among the 4 groups. In the no statin group, the mean levels of LDL-C, non-HDL-C and LDL-C/HDL-C ratio were lower than in the other 3 groups at baseline. The mean levels of triglycerides were higher in both the atorvastatin and pitavastatin groups. Although the rate of hypertensive patients did not show significant difference in the 4 groups, the levels of SBP or DBP were higher in the pitavastatin group.
Laboratory Results and Incidence of MACE
Laboratory results at final observation are shown in Table 2 . LDL-C level in the pravastatin group decreased below 100 mg/dl, whereas the level in the atorvastatin and the pitavas- Dunnett's test demonstrated that pitavastatin had increased HDL-C levels more significantly than atorvastatin (P=0.029), whereas there was no difference in the HDL-C increase in the pravastatin and no statin groups compared with the atorvastatin group (P=0.87 and P=0.80, respectively). The details of MACE are also shown in Table 2 . A total of 88 events occurred in the no statin group, which comprised 12 deaths or MI and 76 coronary revascularizations. Among the patients treated with a statin, a total of 41 events were recorded in the pravastatin group, 31 events in the atorvastatin group and 15 events in the pitavastatin group. Figure 2 shows the cumulative cardiac event rate according to the type of statin. The median observation period from PCI was 19 (interquartile [IQR]: 6-42) months in the no statin group, 39 (IQR: 11-68) months in the pravastatin group, 26 (IQR: 12-49) months in the atorvastatin group and 27 (IQR: 19-42) months in the pitavastatin group. The log-rank test revealed that there were significant differences among the 4 groups in the total cohort (P<0.001, Figure 2A ), in patients with bare metal stent (BMS) (P<0.001, Figure 2B) , and in patients with DES (P<0.001, Figure 2C ).
In addition, the hazard ratio (HR) for each event was investigated, demonstrating that the HR of pitavastatin to atorvastatin for repeated PCI for de novo lesion and TLR was 0.64 (95% confidence interval [CI]: 0.41-0.96, P=0.033) and 0.64 (95%CI: 0.38-1.03, P=0.064), respectively.
Factors Affecting MACE
Univariate analysis using baseline characteristics and concomitant medications showed that 8 factors, including gender, type of CAD, type of device, diabetes, smoking, concomitant medications including ARB, EPA, and each statin, might affect the incidence of cardiac events ( Table 3) . Multivariate- Figure 1 . Percent changes in low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein (HDL-C) in the 4 treatment groups. LDL-C levels in the pravastatin, atorvastatin and pitavastatin groups significantly decreased compared with no statin group. HDL-C level in the pitavastatin group significantly increased compared with the no statin group. Next, to investigate the influence of attained lipid levels at follow-up on cardiac events, another multivariate model was developed using attained LDL-C and HDL-C levels as variables, in which each statin was excluded to avoid confounding with LDL-C and HDL-C levels. Univariate analysis demonstrated that both LDL-C levels (HR: 1.023; 95%CI: 1.018-1.030, by 1 mg/dl increment) and HDL-C levels (HR: 0.978; 95%CI: 0.966-0.990, by 1 mg/dl increment) at follow-up were possible predictive factors for cardiac events. Multivariate-adjusted analysis confirmed that both attained LDL-C levels (HR: 1.021; 95%CI: 1.016-1.027, by 1 mg/dl increment) and HDL-C levels (HR: 0.984; 95%CI: 0.972-0.996, by 1 mg/dl increment) were independent predictive factors for cardiac events after adjusting for type of device, diabetes and smoking. 
Comparison of Preventive Effects of Statins
In order to examine the impact of changes in lipid levels from baseline to follow-up on event incidence, percent changes in LDL-C and HDL-C were added to the multivariate model instead of attained LDL-C and HDL-C levels. Univariate analysis showed that the percent changes of both LDL-C (HR: 1.014; 95%CI: 1.010-1.020, by 1% increment) and HDL-C (HR: 0.991; 95%CI: 0.984-0.997, by 1% increment) from baseline were possible factors for cardiac events, and multivariate-adjusted analysis demonstrated that percent changes of LDL-C (HR: 1.015; 95%CI: 1.010-1.020, by 1% increment) and HDL-C (HR: 0.988; 95%CI: 0.981-0.996, by 1% increment) independently predicted the incidence of cardiac events after adjusting for device, diabetes and smoking. These results suggest that attained lipid levels, as well as changes in the lipid levels from baseline, might be important for preventing cardiac events. Figure 3 shows the Kaplan-Meier curve for cardiac events in the 2 groups divided by median baseline HDL-C level (45 mg/dl). The log-rank test revealed that there were significant difference among the 4 groups in both HDL-C >45 mg/dl (P<0.0001) and HDL-C ≤45 mg/dl (P<0.0001). In patients with a baseline HDL-C level >45 mg/dl, significant differences were observed in the percent change in LDL-C level (P<0.001), but not in HDL-C level (P=0.18) among the 4 groups ( Table 4) . On the other hand, in patients with a baseline HDL-C level ≤45 mg/dl, there were statistically significant differences in not only the percent change in LDL-C level (P<0.001) but also the percent change in HDL-C level (P=0.0038) among the 4 groups. Moreover, only pitavastatin treatment significantly increased HDL-C in patients with a baseline HDL-C ≤45 mg/dl by 21.3±22.7% (P<0.001) compared with no statin.
MACE in Patients With Different Levels of HDL-C at Baseline
Discussion
In the present study it was demonstrated that each statin treatment significantly decreased recurrent cardiac events compared with no statin in patients after PCI, and that pitavastatin treatment was more effective than other statin treatments. Because of the non-randomized, retrospective nature of the study, we could not conclude the superiority of pitavastatin compared with other statins; however, there were differences in the preventive effect on cardiac events among the statins, which might be caused by differences in the strength of lipid management of the statins. Among the cardiac events, hard endpoints such as MI and death from cardiac event were almost suppressed using any statin, while differences in the incidences of TLR and repeated PCI for de novo lesion were observed among the statins. Although the precise mechanism is still unknown, we speculate that differences in the ability to lower LDL-C and increase HDL-C levels among statins lead to significant differences in the anti-atherosclerotic effect.
Our data were consistent with data from PROVE-IT, a trial demonstrating the superiority of intensive lipid-lowering therapy over moderate therapy in Western patients. The composite endpoint of PROVE-IT included all-cause death, MI, PCI, and coronary artery bypass surgery, and atorvastatin especially reduced revascularization significantly. 3 In the present study, atorvastatin and pitavastatin were found to be superior to pravastatin in terms of reducing the occurrence of MACE. Moreover, there were significant positive correlations between percent LDL-C reduction and percent change in the occurrence of MACE. Based on these results, intensive lipid-lowering treatment contributed to a reduction in the recurrent cardiac event rate even in Japanese patients with CAD after PCI.
Our results raised another question about why the occurrence of MACE differed between atorvastatin and pitavastatin even though the 2 statins lowered LDL-C to the same level. We speculate that it resulted from their differing HDL-C raising ability. Several studies have reported a relationship between HDL-C level and the risk of atherosclerosis. 13, 14 Despite a substantial reduction in LDL-C with statin treatment, the risk of cardiovascular events remains high in patients with low HDL-C levels. 12 Moreover, it was reported that the serum HDL-C level was inversely associated with in-stent restenosis. 15, 16 Intervention studies using statins in Japanese patients have revealed the HDL-C elevating effect of statins to be related to regression of coronary artery plaque volume. 17, 18 The present study demonstrated that only pitavastatin significantly increased HDL-C, and that the percent change in HDL-C was a predictor for the occurrence of MACE in multivariate analysis, suggesting that a more effective statin in HDL-C elevating would be expected to prevent the recurrence of cardiac events. The results that patients with baseline HDL-C levels of 45 mg/dl or less showed a significant increase in HDL-C and prevention of MACE by pitavastatin treatment compared with the no statin further supports this suggestion. Treatment focusing on a rise in HDL-C level might be beneficial, especially for patients with low HDL-C level. However, the effect on HDL function should be considered in addition to the HDL-C level in drug treatment. It is possible that to focus only on HDL-C level is insufficient for evaluating the benefit of the drug's efficacy in elevating HDL-C. 5,19-24 For example, it was reported that an inhibitor of cholesteryl ester transfer protein (CETP), torcetrapib, did not prevent the progression of atherosclerosis and conversely elevated overall mortality, despite a remarkable increase in HDL-C. 25, 26 Moreover, it has been suggested that statins have multiple mechanisms for elevating HDL-C. A balance between the 2 abilities of statins would determine their effects on reverse cholesterol transport (RCT): 5 one is to produce apolipoprotein A-I (ApoA-I), which is expected to increase functional HDL particles that can activate RCT and the other is to inhibit CETP, which is speculated to produce dysfunctional HDL with pro-inflammatory and atherogenic properties. 27, 28 From these aspects, it might be beneficial in patients receiving statin treatment to measure ApoA-I levels and CETP concentration or activity in daily clinical practice, because of the difficulty in evaluating HDL functionality. 29, 30 Such measurements were not performed in the present study; however, taking into consideration the reports that pitavastatin showed not only a greater HDL-C-elevating effect but also an ApoA-I-elevating effect than atorvastatin, 9 it might be speculated that the difference in the effect on HDL function between the 2 statins contributed to the difference in the occurrence of MACE.
An alternative possibility might be the difference in the pleiotropic effects of statins. It was reported that pitavastatin had the strongest antiproliferative effect on cultured vascular smooth muscle cells among the statins, and was the only statin that could regenerate vascular endothelial cells. 31 Excessive neointimal proliferation of vascular smooth muscle cells plays a key role in the pathogenesis of in-stent restenosis after BMS placement and neointimal coverage of stent is essential to prevent late in-stent thrombosis after DES placement. 32-34 Taken together, these results suggest one of reason for the lower frequency of TLR in patients treated with pitavastatin.
Study Limitations
First, this study was retrospective and conducted at a single center. Second, the data collection period was long, so chronological bias might exist. The follow-up period of patients with pravastatin was longer than that for the atorvastatin and pitavastatin groups, which might result in greater chance of cardiac events, although those for atorvastatin and pitavastatin were equal. Third, measurements of ApoA-I and C-reactive protein, a good biomarker for inflammation and atherogenicity, were not performed. In addition, this study was limited because cardiac events predominantly consisted of repeated PCI, a relatively soft endpoint. However, the data in the present study are consecutive and were analyzed after the all data were completely collected. Moreover, decision making and PCI treatment were considered to be common because of being a single center study. From these facts, we assume that this bias might be kept to a minimum. Future studies focusing on these problems would be expected.
We concluded that there are differences in the preventive effect on cardiac events among statins in Japanese patients, and that these might be mainly caused by differences in the strength of the HDL-C increasing action as well as the LDL-C lowering power of the various statins.
